Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A July 20, 2026 merger announcement priced Personalis at a major markup through a Tempus AI acquisition structured as a 100% stock transaction, spotlighting the growing cash value of precision-medicine data platforms.
THE APEX TIMES
THE APEX TIMES
A sharp rally in Moderna Inc.’s stock reverses a bearish period for traders who had bet the biotech’s slump would persist, according to a market report.
THE APEX TIMES
A new report says Moderna is applying individualized mRNA technology first built for infectious disease to a cancer strategy designed to help the immune system recognize and attack tumor cells that reappear.
THE APEX TIMES
Shares in Moderna rallied sharply after market coverage of Phase III results connected to an investigational, autogene-style cancer vaccine program with MSD. The companies have not, in the material provided here, laid out full commercialization timelines or detailed regulatory milestones.
THE APEX TIMES
A personalized mRNA vaccine co-developed by Moderna and Merck & Co. showed reduced melanoma recurrence in a large late-stage trial, reviving hopes that the approach can treat one of the deadliest forms of skin cancer.
THE APEX TIMES
Pfizer is positioning berobenatide, a potential monthly obesity treatment, as part of its push to win share in a market dominated by daily and weekly GLP-1 therapies.
THE APEX TIMES
A market report says an mRNA treatment developed by Moderna in combination with Merck’s Keytruda achieved success in a Phase 3 cancer trial, a milestone investors track closely for what could be one of the first mRNA vaccines to reach that late-stage bar in oncology.
THE APEX TIMES
A reported positive readout in a late-stage melanoma trial helped revive investor sentiment toward Moderna, with at least one analyst projecting long-term sales potential tied to the treatment.
THE APEX TIMES
The biotech’s stock more than doubled following reported Phase 3 success versus the existing standard of care, a move that also appears to have crushed losses for investors betting against the company.
